Hofseth Biocare ASA: SHARE CAPITAL INCREASE REGISTERED
October 27 2016 - 3:25AM
Reference is made to the prospectus (the
"Prospectus") dated 30 September 2016 concerning, inter alia, the
subsequent offering (the "Subsequent Offering") of minimum 1 and
maximum 13,333,334 new shares (the "Offer Shares") in Hofseth
BioCare ASA ("HBC" or the "Company", ticker "HBC") and the stock
exchange notice published on 17 October 2016 regarding allocation
of Offer Shares in the Subsequent Offering.
The share capital increase related to the
Subsequent Offering has now been registered with the Norwegian
Register of Business Enterprises. The share capital has been
increased with NOK 1,027,494 through issuance of 1,027,494 new
shares.
The new share capital is thus NOK 233,499,759
divided by 233,499,759 shares, each with a par value of NOK 1.
The new shares will be listed and become tradable
on Oslo Axess upon duly registration in the VPS-register on 27
October 2016.
For further information, please contact:
Jon Olav Ødegård, CFO of Hofseth BioCare ASA
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no
About Hofseth BioCare ASA:
HBC is a Norwegian biotech company that offers
high-value ingredients and finished products for humans and pets.
The company is founded on the core values of sustainability,
traceability and optimal utilization of natural resources. Through
an innovative hydrolysis technology, HBC is able to preserve the
quality of salmon oil, proteins and calcium, prepared of fresh
salmon off-cuts. HBC's objective is to contribute to the efficient
use of marine resources and deliver quality products for
ingredients and finished consumer products in the nutrition
market.
Hofseth BioCare's headquarters are located in
Ålesund, Norway with branches in Oslo, Chicago, Mumbai and Tokyo.
HBC is listed on Oslo Stock Exchange Axess list with ticker "HBC".
More information about Hofseth BioCare at www.hofsethbiocare.com
and www.facebook.com/hofsethbiocare
This information is subject
to the disclosure requirements pursuant to section 5-12 of the
Norwegian Securities Trading Act.
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Hofseth Biocare ASA via Globenewswire